0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Glycoprotein (RABV)

Glycoprotein (RABV)

Brief Information

Name:Thrombospondin 1
Target Synonym:TSP,Glycoprotein G,THBS1,Thrombospondin-1p180,TSP1,Thrombospondin-P50,Thrombospondin-1,THBS-1,TSP-1,THBS,Thrombospondin 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GLN-M645-SPR
 Glycoprotein (RABV) SPR

Monoclonal Anti-Glycoprotein G(Lyssavirus rabies) Antibody, Human IgG1 (4A7) (Cat. No. GLN-M645) captured on Protein A Chip can bind Rabies virus Glycoprotein G, His Tag (Cat. No. RAG-V55H5) with an affinity constant of 1.25 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

GLN-RF5E3-ELISA
 Glycoprotein (RABV) ELISA

Immobilized FITC-Labeled Rabies virus (strain CVS-11) Glycoprotein G, His Tag (Cat. No. GLN-RF5E3) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-2, Fc Tag with a linear range of 0.1-3 ng/mL (QC tested).

Customer Reviews

Synonym Name

Glycoprotein

Background

Rabies virus (RABV), scientific name Rabies lyssavirus, is a deadly neurotropic virus that causes rabies in humans and animals. Rabies virus has an extremely wide host range and its transmission most often occur through the saliva of animals. Without intervention prior to disease progression, rabies has the highest case fatality of any infectious disease. RABV contains a single-stranded negative-sense RNA genome that encodes five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and RNA-dependent RNA polymerase (L). Among these viral proteins, the RABV glycoprotein (RABV-G) is a pivotal player mediating virus entry and the major target of neutralizing antibodies, thus a key factor for vaccine and drug design.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VT-1021 VT-1021 Phase 1 Clinical Vigeo Therapeutics Inc Solid tumours Details
VT-1021 VT-1021 Phase 1 Clinical Vigeo Therapeutics Inc Solid tumours Details

This web search service is supported by Google Inc.

totop

Laisser un message